Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults
NCT03220724Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2017
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of CH505TF gp120, CH505W53, CH505w78 and CH505 M5 gp120 in human immunodeficiency virus infection (HIV) (9 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms and 6 more. Started Aug 2017; status: completed.
02
Drugs
CH505TF gp120CH505W53CH505w78CH505 M5 gp120
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03220724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220724.